hydrochlorothiazide has been researched along with Headache in 17 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
Headache: The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This 8-week study in Korea aimed to evaluate the efficacy and tolerability of a telmisartan/amlodipine + hydrochlorothiazide (TAH) combination versus telmisartan/amlodipine (TA) combination in patients with essential hypertension that did not respond appropriately to 4-week treatment with TA." | 9.27 | Efficacy and Tolerability of Telmisartan/Amlodipine + Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI St ( Ahn, JC; Ahn, JH; Ahn, YK; Cha, DH; Chae, IH; Cho, DK; Cho, SK; Choi, YJ; Hong, SJ; Hong, TJ; Hyon, MS; Jang, JY; Jeon, DW; Jeong, JO; Kim, BS; Kim, HS; Kim, SH; Nam, CW; Oh, YS; Park, SH; Rha, SW; Song, JM; Sung, KC; Won, KH; Yang, TH; Yoo, BS; Yoo, KD; Yoon, YW, 2018) |
| " The authors report on an 8-week double-blind, randomized study of African American patients with stage 2 hypertension that compared brachial and central BP responses (substudy of 53 patients) to combination aliskiren/hydrochlorthiazide (HCTZ) and amlodipine monotherapy." | 9.15 | Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial. ( Ferdinand, KC; Pool, J; Purkayastha, D; Townsend, R; Weitzman, R, 2011) |
| "To examine the effect of telmisartan or hydrochlorothiazide on the control of urinary albumin excretion (UAE) in patients with isolated systolic hypertension (ISH) unselected for albuminuria in a pre-planned substudy of a large, multicentre, double-blind, placebo-controlled, randomized study." | 9.11 | The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial. ( de Zeeuw, D; Köster, J; Manolis, AJ; Navis, G; Reid, JL; Vogt, L, 2005) |
| "The aim of this analysis was to assess the efficacy and safety of the angiotensin II type 1 receptor antagonist (angiotensin receptor blocker [ARB]) olmesartan medoxomil in elderly patients with either essential hypertension or isolated systolic hypertension." | 7.75 | Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension : efficacy and safety data from clinical trials. ( Heagerty, AM; Mallion, JM, 2009) |
| "1%) were the clinical adverse experiences most often reported in patients treated with losartan." | 6.68 | Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. ( Dunlay, MC; Goldberg, AI; Sweet, CS, 1995) |
| " Both nisoldipine and the diuretic had a flat dose-response curve." | 6.66 | Monotherapy with the calcium channel antagonist nisoldipine for systemic hypertension and comparison with diuretic drugs. ( Daniels, AR; Opie, LH, 1987) |
| "This 8-week study in Korea aimed to evaluate the efficacy and tolerability of a telmisartan/amlodipine + hydrochlorothiazide (TAH) combination versus telmisartan/amlodipine (TA) combination in patients with essential hypertension that did not respond appropriately to 4-week treatment with TA." | 5.27 | Efficacy and Tolerability of Telmisartan/Amlodipine + Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI St ( Ahn, JC; Ahn, JH; Ahn, YK; Cha, DH; Chae, IH; Cho, DK; Cho, SK; Choi, YJ; Hong, SJ; Hong, TJ; Hyon, MS; Jang, JY; Jeon, DW; Jeong, JO; Kim, BS; Kim, HS; Kim, SH; Nam, CW; Oh, YS; Park, SH; Rha, SW; Song, JM; Sung, KC; Won, KH; Yang, TH; Yoo, BS; Yoo, KD; Yoon, YW, 2018) |
| " The authors report on an 8-week double-blind, randomized study of African American patients with stage 2 hypertension that compared brachial and central BP responses (substudy of 53 patients) to combination aliskiren/hydrochlorthiazide (HCTZ) and amlodipine monotherapy." | 5.15 | Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial. ( Ferdinand, KC; Pool, J; Purkayastha, D; Townsend, R; Weitzman, R, 2011) |
| "To examine the effect of telmisartan or hydrochlorothiazide on the control of urinary albumin excretion (UAE) in patients with isolated systolic hypertension (ISH) unselected for albuminuria in a pre-planned substudy of a large, multicentre, double-blind, placebo-controlled, randomized study." | 5.11 | The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial. ( de Zeeuw, D; Köster, J; Manolis, AJ; Navis, G; Reid, JL; Vogt, L, 2005) |
| "The aim of this analysis was to assess the efficacy and safety of the angiotensin II type 1 receptor antagonist (angiotensin receptor blocker [ARB]) olmesartan medoxomil in elderly patients with either essential hypertension or isolated systolic hypertension." | 3.75 | Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension : efficacy and safety data from clinical trials. ( Heagerty, AM; Mallion, JM, 2009) |
| " Adverse events (AEs) were reported in 75." | 2.82 | Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study. ( Barger, B; Handley, A; Lloyd, E; Roberts, A, 2016) |
| "1%) were the clinical adverse experiences most often reported in patients treated with losartan." | 2.68 | Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. ( Dunlay, MC; Goldberg, AI; Sweet, CS, 1995) |
| " Both nisoldipine and the diuretic had a flat dose-response curve." | 2.66 | Monotherapy with the calcium channel antagonist nisoldipine for systemic hypertension and comparison with diuretic drugs. ( Daniels, AR; Opie, LH, 1987) |
| "Aggressive treatment of hypertension resulted in complete resolution of the clinical and radiologic features of the syndrome." | 1.43 | Does this patient have hypertensive encephalopathy? ( Argyropoulou, MI; Christopoulou, F; Elisaf, M; Kosta, P; Rizos, EC, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (29.41) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Bossoni, S | 1 |
| Chiesa, L | 1 |
| Giustina, A | 1 |
| Sung, KC | 1 |
| Oh, YS | 1 |
| Cha, DH | 1 |
| Hong, SJ | 1 |
| Won, KH | 1 |
| Yoo, KD | 1 |
| Rha, SW | 1 |
| Ahn, YK | 1 |
| Ahn, JC | 1 |
| Jang, JY | 1 |
| Hong, TJ | 1 |
| Cho, SK | 1 |
| Park, SH | 1 |
| Hyon, MS | 1 |
| Nam, CW | 1 |
| Chae, IH | 1 |
| Yoo, BS | 1 |
| Song, JM | 1 |
| Jeong, JO | 1 |
| Yoon, YW | 1 |
| Kim, BS | 1 |
| Yang, TH | 1 |
| Cho, DK | 1 |
| Kim, SH | 1 |
| Choi, YJ | 1 |
| Ahn, JH | 1 |
| Jeon, DW | 1 |
| Kim, HS | 1 |
| Chen, SH | 1 |
| Karanjia, R | 1 |
| Chevrier, RL | 1 |
| Marshall, DH | 1 |
| Handley, A | 1 |
| Lloyd, E | 1 |
| Roberts, A | 1 |
| Barger, B | 1 |
| Christopoulou, F | 1 |
| Rizos, EC | 1 |
| Kosta, P | 1 |
| Argyropoulou, MI | 1 |
| Elisaf, M | 1 |
| Fonseca, J | 1 |
| Oliveira, K | 1 |
| Cordeiro, M | 1 |
| Real, MV | 1 |
| Heagerty, AM | 1 |
| Mallion, JM | 1 |
| Ferdinand, KC | 1 |
| Pool, J | 1 |
| Weitzman, R | 1 |
| Purkayastha, D | 1 |
| Townsend, R | 1 |
| Vogt, L | 1 |
| Navis, G | 1 |
| Köster, J | 1 |
| Manolis, AJ | 1 |
| Reid, JL | 1 |
| de Zeeuw, D | 1 |
| Goldberg, AI | 2 |
| Dunlay, MC | 1 |
| Sweet, CS | 2 |
| Ruilope, LM | 1 |
| Simpson, RL | 1 |
| Toh, J | 1 |
| Arcuri, KE | 1 |
| Benz, JR | 1 |
| Black, HR | 1 |
| Graff, A | 1 |
| Reed, A | 1 |
| Fitzsimmons, S | 1 |
| Shi, Y | 1 |
| Helgeland, A | 1 |
| Strømmen, R | 1 |
| Hagelund, CH | 1 |
| Tretli, S | 1 |
| Hoss, DM | 1 |
| Nierenberg, DW | 1 |
| Groom, P | 1 |
| Simpson, RJ | 1 |
| Singh, B | 1 |
| Ward, DE | 1 |
| Peers, E | 1 |
| Richardson, PD | 1 |
| Daniels, AR | 1 |
| Opie, LH | 1 |
| Packard, RC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-Blind, Multi-Center, Phase 3 Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Hydrochlorothiazide Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients Not Controlled by[NCT02738632] | Phase 3 | 300 participants (Anticipated) | Interventional | 2015-05-31 | Completed | ||
| An 8 Week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ Versus Amlodipine in African American Patients With Stage 2 Hypertension[NCT00739596] | Phase 4 | 332 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To compare the percentage of patients achieving BP control (<140/90 mm Hg) after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension. (NCT00739596)
Timeframe: 8 weeks
| Intervention | Cumulative percentage of participants (Number) |
|---|---|
| Aliskiren HCTZ | 63.6 |
| Amlodipine | 62.3 |
To compare the percentage of responders after 8 weeks of treatment with an aliskiren HCTZ based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension: [ Responders were defined as patients with MSSBP < 140 mm Hg or a decrease from baseline ≥ 20 mm Hg at 1st response. A response was counted when a patient first achieved MSSBP < 140 mm Hg or a decrease from baseline ≥ 20 mm Hg.] (NCT00739596)
Timeframe: 8 weeks
| Intervention | Cumulative percentage of responders (Number) |
|---|---|
| Aliskiren HCTZ | 84.6 |
| Amlodipine | 90.7 |
To assess the change from baseline in mean sitting diastolic blood pressure (MSDBP) after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension. (NCT00739596)
Timeframe: Baseline and 8 weeks
| Intervention | mm Hg (Mean) | ||
|---|---|---|---|
| Baseline | Week 8 | Change from Baseline to Week 8 | |
| Aliskiren HCTZ | 96.0 | 86.0 | -10.0 |
| Amlodipine | 95.0 | 84.0 | -11.0 |
To compare the change from baseline in mean sitting pulse pressure (MSPP) after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension. (NCT00739596)
Timeframe: Baseline and 8 weeks
| Intervention | mm Hg (Mean) | ||
|---|---|---|---|
| Baseline | Week 8 | Change from Baseline to Week 8 | |
| Aliskiren HCTZ | 72.2 | 52.7 | -19.4 |
| Amlodipine | 73.1 | 55.1 | -18.0 |
To assess the change from baseline in MSSBP after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension. (NCT00739596)
Timeframe: Baseline and 8 weeks
| Intervention | mm Hg (Mean) | ||
|---|---|---|---|
| Baseline | Week 8 | Change from baseline to Week 8 | |
| Aliskiren HCTZ | 168.2 | 138.8 | -29.4 |
| Amlodipine | 168.1 | 139.1 | -29.0 |
10 trials available for hydrochlorothiazide and Headache
| Article | Year |
|---|---|
Efficacy and Tolerability of Telmisartan/Amlodipine + Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI St
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Dizzine | 2018 |
Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study.
Topics: Adult; Aged; Benzimidazoles; Chlorthalidone; Cohort Studies; Dizziness; Drug Therapy, Combination; E | 2016 |
Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial.
Topics: Adult; Amides; Amlodipine; Antihypertensive Agents; Black or African American; Blood Pressure; Brach | 2011 |
The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensi | 2005 |
Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Conver | 1995 |
Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients.
Topics: Adult; Antihypertensive Agents; Asthenia; Biphenyl Compounds; Blood Pressure; Controlled Clinical Tr | 1996 |
Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy.
Topics: Adult; Angiotensin II; Antihypertensive Agents; Dizziness; Dose-Response Relationship, Drug; Double- | 1998 |
Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. A comparative multicentre study in general practice in Norway.
Topics: Adult; Aged; Atenolol; Blood Glucose; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; | 1986 |
A double-blind comparison of felodipine and hydrochlorothiazide added to metoprolol to control hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Dizziness; Double-Bl | 1988 |
Monotherapy with the calcium channel antagonist nisoldipine for systemic hypertension and comparison with diuretic drugs.
Topics: Adult; Amiloride; Calcium Channel Blockers; Diuretics; Dose-Response Relationship, Drug; Double-Blin | 1987 |
7 other studies available for hydrochlorothiazide and Headache
| Article | Year |
|---|---|
Severe hypocalcemia in a thyroidectomized woman with Covid-19 infection.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Calcium; Calcium Gluconate; Coronav | 2020 |
Bilateral acute angle closure glaucoma associated with hydrochlorothiazide-induced hyponatraemia.
Topics: Aged; Antihypertensive Agents; Diagnosis, Differential; Female; Glaucoma, Angle-Closure; Headache; H | 2014 |
Does this patient have hypertensive encephalopathy?
Topics: Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Brain; Carbazoles; Carvedilol; Computed Tom | 2016 |
Posterior reversible encephalopathy syndrome: A case report.
Topics: Amiloride; Antihypertensive Agents; Child; Diagnosis, Differential; Diagnostic Imaging; Diuretics; E | 2019 |
Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension : efficacy and safety data from clinical trials.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Dizziness; D | 2009 |
Severe shaking chills and fever following hydrochlorothiazide administration.
Topics: Diarrhea; Drug Hypersensitivity; Female; Fever; Headache; Humans; Hydrochlorothiazide; Middle Aged; | 1988 |
Propranolol ... not guilty.
Topics: Drug Combinations; Headache; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Propranol | 1987 |